Margin trendWarning
영업외손익 급변 (영업이익 대비 902% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Ilsung Is
003120 · KOSPI₩20,550-0.48%
2026-09-04 closeIlsung Is last closed at ₩20,550 (-0.48%) on 2026-09-04. Signals today: Death cross, VCP. Listed on KOSPI; price, financials and dividends update daily after market close.
Loading chart…
Close
데드크로스 · 0d 전
New high + volume — the real recordrecord · not a prediction
Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p
Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.
Signal history
| Date | Signal | +20 trading days |
|---|---|---|
A record, not a prediction.
How this is calculated
"·" means fewer than 20 trading days have passed since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Trade plan
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
A calculator · not advice or a guarantee
Financials & valuation at a glance
A
Overall: 건강관리 33/291 · top 11%
Factor composite · relative position in sector
PER 20.87 · PBR 0.71 — own-history percentile 65/100 · 48/100
Open self-history band
PER65/100
PBR48/100
Factual information · not investment advice
Past reported results · not investment advice
More — deeper indicators
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 26 consecutive years · Raised 0 consecutive years · Yield 4.87% (based on 2025 payment of 1,000원) · 3-year growth +88.2%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 42.47
Distress
Grey
Safe
- Altman Z''
- 42.47
- Beneish M-Score
- -2.17
- Sloan accrual
- 4.37%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Industry structure
KRAs of 2026-09-05건강관리
This stock is in 건강관리: revenue rank 146 of 287, share 0.1%.
146 / 2870.1%revenue share
Who dominates this industry?
- 1삼성바이오로직스7.3%
- 2셀트리온5.7%
- 3녹십자홀딩스3.5%
- 4유한양행3.3%
- 5대웅3.1%
- 6일성아이에스0.1%
Concentration
DistributedCR3 16.6%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 31.61
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 13.9
- Median P/B
- 1.47
- Level
- 넓음
- n
- 263
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -4.7%
- Interest coverage
- -89.6x
- Return on equity (ROE)
- 3.4%
Operating margin −5pp
Operating lossInterest coverageBase -89.6x adverse case -184.9x
Return on equity (ROE)Base 3.4% adverse case -1.7%
Revenue −15%
Interest coverage riskInterest coverageBase -89.6x adverse case -76.2x
Return on equity (ROE)Base 3.4% adverse case -0.7%
Interest rate +2pp
Interest coverage riskInterest coverageBase -89.6x adverse case -12x
Return on equity (ROE)Base 3.4% adverse case -0.9%
Interest coverage limit
Already below the limit by 4.8ppInterest coverage limit at an operating margin of 0.1%
Interest expense coverage threshold
Key suppliers · Annual report
Annual reportDART · 2026-03-18Suppliers disclosed by the company in its 2026-03-18 annual report.
Suppliers without disclosed amount
AmoxycillinGSKIohexolCamostatMesylateONOAlfacalcidolTEIJINSevofluraneTIANJINBottleOral+3 more
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
5%+ major-holding disclosures
- 윤석근33.51%2026-07-23 · 증감 -4.44%p
Connections
AI-extracted related companies · for reference
Competitors
대웅제약Price comovement r=0.15 (1 year)유한양행Price comovement r=0.14 (1 year)종근당Price comovement r=0.17 (1 year)GC녹십자한미약품Price comovement r=0.14 (1 year)보령Price comovement r=0.34 (1 year)동아에스티Price comovement r=0.30 (1 year)JW중외제약Price comovement r=0.25 (1 year)한국유나이티드제약일동제약Price comovement r=0.14 (1 year)
Recent filings
Ilsung Is's latest filings on Korea's DART. Open a headline for a reference summary and the original.
Source: DART (Korea electronic disclosure)
About Ilsung Is
- What technical signals does Ilsung Is (003120) have?
- Ilsung Is current technical signals: death cross (5_20, 0d ago).
- Is Ilsung Is a cup-and-handle pattern?
- No. Ilsung Is has no valid cup-and-handle signal right now.
- What are Ilsung Is's financials and valuation?
- Ilsung Is's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.
Like these rules? Backtest them.
Run this signal on this ticker in the free backtest builder — same window, no install.
Backtest this rule ↗Quantus Signal · live data · not investment advice · Privacy Policy